# A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene

> **NCT07185347** · PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 70 (estimated)

## Conditions studied

- Spinocerebellar Ataxia 27B (SCA27B)

## Interventions

- **DRUG:** Fampridine 10 mg prolonged-release tablet (per os)
- **DRUG:** Placebo (tablets per os)

## Key facts

- **NCT ID:** NCT07185347
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-21
- **Primary completion:** 2027-05-21
- **Final completion:** 2027-05-21
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07185347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07185347, "A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07185347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*